Ascelia Pharma AB (publ) - Asset Resilience Ratio

Latest as of September 2021: 0.00%

Ascelia Pharma AB (publ) (ACE) has an Asset Resilience Ratio of 0.00% as of September 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ACE working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Skr0.00

≈ $0.00 USD Cash + Short-term Investments

Total Assets

Skr365.04 Million

≈ $39.28 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2023)

This chart shows how Ascelia Pharma AB (publ)'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Ascelia Pharma AB (publ) total assets.

Liquid Assets Composition Over Time

This chart breaks down Ascelia Pharma AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Ascelia Pharma AB (publ) (ACE) investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr0.00	0%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr0.00	0.00%

Asset Resilience Insights

Limited Liquidity: Ascelia Pharma AB (publ) maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

Ascelia Pharma AB (publ) Industry Peers by Asset Resilience Ratio

Compare Ascelia Pharma AB (publ)'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Ascelia Pharma AB (publ) (2016–2023)

The table below shows the annual Asset Resilience Ratio data for Ascelia Pharma AB (publ).

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	0.00%	Skr1.00K ≈ $107.62	Skr87.07 Million ≈ $9.37 Million	--
2020-12-31	0.00%	Skr0.00 ≈ $0.00	Skr255.37 Million ≈ $27.48 Million	--
2019-12-31	30.26%	Skr75.71 Million ≈ $8.15 Million	Skr250.23 Million ≈ $26.93 Million	+4.14pp
2018-12-31	26.12%	Skr75.08 Million ≈ $8.08 Million	Skr287.42 Million ≈ $30.93 Million	+26.18pp
2016-12-31	-0.06%	Skr-47.00K ≈ $-5.06K	Skr80.39 Million ≈ $8.65 Million	--

pp = percentage points

About Ascelia Pharma AB (publ)

ST:ACE Sweden Biotechnology

Market Cap

$8.55 Million

Skr79.42 Million SEK

Market Cap Rank

#27545 Global

#602 in Sweden

Share Price

Skr0.63

Change (1 day)

+9.25%

52-Week Range

Skr0.48 - Skr3.85

All Time High

Skr900.24